Welcome to our dedicated page for Longeveron SEC filings (Ticker: LGVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Longeveron Inc. filings document a clinical-stage biotechnology issuer developing laromestrocel, an investigational allogeneic cellular therapy, and its related regulatory, financing, governance, and listing disclosures. Form 8-K reports cover FDA communications, clinical-development updates, material agreements, executive and board compensation matters, shareholder meeting actions, and Nasdaq continued-listing notices.
Registration statements and event reports also identify LGVN’s Class A common stock, Nasdaq Capital Market listing, emerging growth company status, and financing-related securities disclosures. The filing record ties the company’s public-company reporting to clinical and regulatory development of laromestrocel, stockholder voting matters, and capital resources used to fund biotechnology operations.
Longeveron Inc. reported that Chief Medical Officer Nataliya Agafonova acquired 250,000 shares of its Class A Common Stock through an award of time-based vesting Restricted Stock Units (RSUs) on May 1, 2026 at a stated price of $0.00 per share.
After this RSU award, she directly holds 453,419 Class A shares, which include RSUs subject to future vesting. The award reflects a non-cash equity grant classified as a grant, award, or other acquisition under insider reporting rules.
Locklear Lisa reported acquisition or exercise transactions in this Form 4 filing.
Longeveron Inc. Chief Financial Officer Lisa Locklear received an award of 250,000 shares of Class A Common Stock as time-based vesting Restricted Stock Units (RSUs). The grant was recorded at $0.00 per share, reflecting a compensation award rather than an open-market purchase.
After this award, Locklear directly holds 465,686 shares of Class A Common Stock, which the footnotes state includes RSUs that are still subject to future vesting conditions.
Longeveron Inc. is soliciting proxies for its 2026 virtual Annual Meeting to be held on July 1, 2026. Key items include election of three Class II directors, a proposed increase in authorized Class A shares from 84,295,000 to 175,000,000, a possible reverse stock split in the range 1-for-2 to 1-for-20, and an amendment to expand the 2021 Incentive Award Plan.
The record date for voting is May 11, 2026, and the proxy materials, including the Annual Report for the year ended December 31, 2025, are available online at the meeting portal.
Longeveron Inc. registered 30,865,385 shares of Class A common stock for resale by certain selling stockholders. The prospectus covers (i) 6,013,384 issued shares, (ii) 22,832,770 shares issuable on conversion of Series A preferred stock, and (iii) up to 2,019,231 shares issuable on exercise of placement agent warrants.
The company will not receive proceeds from these resales, except for up to $1,312,500 if the PA Warrants are exercised for cash. Shares outstanding prior to the Private Placement were 21,783,749; fully converted/exercised outstanding would be 52,649,134 as disclosed. The registration satisfies contractual registration rights and permits the listed selling stockholders to sell shares on-market or in private transactions.
Longeveron Inc. describes changes to executive and director compensation tied to a prior cost-cutting plan. Earlier in 2026, the company temporarily reduced pay for its executive team and Board by about 25% to 50% while reviewing its cash runway and cost structure.
After closing a financing transaction reported on March 12, 2026, and determining it had the financial capacity, Longeveron repaid executives and directors the difference between their original and reduced compensation for the reduction period. In addition, the Compensation Committee approved equity awards of 250,000 restricted stock units for each executive other than the Executive Chairman and 500,000 restricted stock units for the Chief Executive Officer. These RSUs are to be granted on May 1, 2026 and vest quarterly over three years starting July 1, 2026 under the company’s Third Amended and Restated 2021 Incentive Award Plan.
Longeveron Inc. is registering 30,865,385 shares of Class A common stock for resale by existing investors, including shares already issued, shares issuable from preferred stock conversion, and shares underlying placement agent warrants. The company will not receive proceeds from these resales, but could receive up to $1.31 million if all placement agent warrants are exercised in cash.
Longeveron is a clinical-stage biotech focused on its cell therapy candidate laromestrocel (Lomecel-B®) for rare pediatric heart disease (HLHS), Alzheimer’s disease, pediatric dilated cardiomyopathy and aging-related frailty. The filing highlights a recent $15.9 million private placement, substantial doubt about the company’s ability to continue as a going concern, and Nasdaq minimum bid-price noncompliance that could lead to a reverse split or potential delisting if not cured.
Longeveron Inc. General Counsel and Secretary Paul T. Lehr reported a routine tax-related share disposition. On the vesting of a restricted stock unit award, 5,611 shares of Class A common stock were withheld at $1.12 per share to satisfy tax obligations.
Following this tax-withholding event, Lehr directly holds 338,566 shares of Class A common stock, which the disclosure notes includes restricted stock units that are subject to future vesting.
Longeveron Inc. Chief Medical Officer Nataliya Agafonova reported a routine tax-related share disposition. On the vesting of a restricted stock unit award, 13,145 shares of Class A common stock were withheld at $1.12 per share to satisfy tax obligations, rather than sold in the open market.
After this withholding, she directly holds 203,419 shares of Class A common stock, which includes RSUs that are still subject to future vesting. The filing reflects compensation-related share vesting mechanics, not an active decision to buy or sell shares.
Longeveron Inc. Chief Financial Officer Lisa Locklear reported a routine tax-related share disposition. On April 1, 2026, 13,145 shares of Class A Common Stock were withheld at $1.12 per share to satisfy tax obligations tied to vesting of a restricted stock unit award.
After this withholding, Locklear directly holds 215,686 shares of Class A Common Stock, which the disclosure states includes RSUs that are still subject to future vesting. The filing does not show any open-market buying or selling activity.